Ads
related to: new drug to stop pahassistantfish.com has been visited by 10K+ users in the past month
Search results
Results from the WOW.Com Content Network
Merck said its drug met the main goal of significantly reducing the time to disease worsening, lung transplantation or death in a late-stage study of 172 patients with advanced stages of the ...
Selexipag, sold under the brand name Uptravi, is a medication developed by Actelion for the treatment of pulmonary arterial hypertension (PAH). [3] [4] Selexipag and its active metabolite, ACT-333679 (or MRE-269, the free carboxylic acid), are agonists of the prostacyclin receptor, which leads to vasodilation in the pulmonary circulation. [5]
The Chronic Thromboembolic Pulmonary Hypertension sGC-Stimulator Trial (CHEST) was a randomized, placebo-controlled trial aimed to analyse the efficacy and safety of riociguat in CTEPH patients. [20] After a 16-week riociguat treatment the patient's exercise capacity were evaluated by measuring the change in the six-minute walk test (6-MWT). [21]
Ambrisentan is a drug that blocks endothelin, an endogenous hormone found in higher quantities in patients with pulmonary arterial hypertension. Endothelin binds to two receptors, ET A and ET B . ET A is responsible for cell growth in the vessels as well as vasoconstriction , while ET B plays a role in vasodilation , endothelin 1 clearance, and ...
For premium support please call: 800-290-4726 more ways to reach us
Arena (ARNA) inks a deal to out-license global rights to its phase III candidate, ralinepag, to United Therapeutics. Shares of the company rally 22% following this news.
Ads
related to: new drug to stop pahassistantfish.com has been visited by 10K+ users in the past month